J&J reports promising Ebola vaccine data

accreditation
0:00
play article
Subscribers can listen to this article
A girl gets inoculated with an Ebola vaccine on November 22, 2019 in Goma, the Democratic Republic of the Congo
A girl gets inoculated with an Ebola vaccine on November 22, 2019 in Goma, the Democratic Republic of the Congo
Pamela Tulizo/AFP via Getty Images
  • Johnson & Johnson said its Ebola vaccine regimen demonstrated antibody immune responses in adults and children.
  • The two-dose regimen was well-tolerated and induced antibody responses to the Zaire ebolavirus species 21 days after the second dose in 98% of all participants.
  • J&J added that there were no safety signals of concern.


Johnson & Johnson said on Monday its Ebola vaccine regimen demonstrated antibody immune responses in adults and children, citing data published in the Lancet Infectious Diseases journal.

The two-dose regimen was well-tolerated and induced antibody responses to the Zaire ebolavirus species 21 days after the second dose in 98% of all participants, the company said, citing data from a late-stage trial.

The regimen, Zabdeno and Mvabea, generated immune responses that persisted in adults for at least two years.

J&J added that there were no safety signals of concern.

J&J's Chief Scientific Officer Paul Stoffels said:

These peer-reviewed data support the prophylactic use of the Johnson & Johnson Ebola vaccine regimen to protect people at risk of Ebola, which is essential to our vision of preventing Ebola outbreaks before they can begin.

The company added that a booster shot administered two years after the initial vaccination induced a strong immune response within seven days.

Ebola typically kills about half of those it infects, although vaccines and new treatments have proven highly effective in reducing fatality rates.

Last month, the World Health Organisation warned that on top of the Covid-19 pandemic, West Africa is facing new outbreaks of the viral haemorrhagic fevers Marburg and Ebola, risking huge strains on ill-equipped health systems.

J&J's vaccine regimen had received European approval in July 2020 and prequalification from the WHO, which allows medicines to be procured by developing countries, in April 2021.


Never miss a story. Choose from our range of newsletters to get the news you want delivered straight to your inbox.

We live in a world where facts and fiction get blurred
In times of uncertainty you need journalism you can trust. For only R75 per month, you have access to a world of in-depth analyses, investigative journalism, top opinions and a range of features. Journalism strengthens democracy. Invest in the future today.
Subscribe to News24
Lockdown For
DAYS
HRS
MINS
Voting Booth
After the opening weekend of URC action, what did you make of the South African struggles?
Please select an option Oops! Something went wrong, please try again later.
Results
It exposed the quality of South African rugby...
40% - 366 votes
There were positives to take
7% - 65 votes
We shouldn't read too much into one weekend
17% - 159 votes
It will take the SA sides time to adjust to the new competition
36% - 330 votes
Vote
Rand - Dollar
15.05
-0.7%
Rand - Pound
20.64
-1.0%
Rand - Euro
17.62
-0.5%
Rand - Aus dollar
10.96
-1.0%
Rand - Yen
0.14
-0.5%
Gold
1,755.97
+0.3%
Silver
22.80
+1.7%
Palladium
1,967.50
-0.4%
Platinum
989.00
+0.2%
Brent Crude
78.09
+1.1%
Top 40
57,895
+0.4%
All Share
64,317
+0.4%
Resource 10
57,993
+1.3%
Industrial 25
83,139
+0.3%
Financial 15
14,167
-1.1%
All JSE data delayed by at least 15 minutes Iress logo
Editorial feedback and complaints

Contact the public editor with feedback for our journalists, complaints, queries or suggestions about articles on News24.

LEARN MORE